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Background: Live attenuated viruses are among our most potent and effective vaccines. For human
immunodeficiency virus, however, a live attenuated strain could present substantial safety concerns. We have used
the live attenuated rubella vaccine strain RA27/3 as a vector to express SIV and HIV vaccine antigens because its
safety and immunogenicity have been demonstrated in millions of children. One dose protects for life against
rubella infection. In previous studies, rubella vectors replicated to high titers in cell culture while stably expressing
SIV and HIV antigens. Their viability in vivo, however, as well as immunogenicity and antibody persistence, were
unknown.
Results: This paper reports the first successful trial of rubella vectors in rhesus macaques, in combination with DNA
vaccines in a prime and boost strategy. The vectors grew robustly in vivo, and the protein inserts were highly
immunogenic. Antibody titers elicited by the SIV Gag vector were greater than or equal to those elicited by natural
SIV infection. The antibodies were long lasting, and they were boosted by a second dose of replication-competent
rubella vectors given six months later, indicating the induction of memory B cells.
Conclusions: Rubella vectors can serve as a vaccine platform for safe delivery and expression of SIV and HIV
antigens. By presenting these antigens in the context of an acute infection, at a high level and for a prolonged
duration, these vectors can stimulate a strong and persistent immune response, including maturation of memory B
cells. Rhesus macaques will provide an ideal animal model for demonstrating immunogenicity of novel vectors and
protection against SIV or SHIV challenge.
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Despite the urgent need for a safe and potent vaccine
against HIV, efforts to produce a vaccine have been
thwarted by antigenic variation, weak immunogenicity of
critical epitopes, and short duration of the immune
response to HIV vaccine antigens [1-3]. For other
viruses, such as measles, mumps and rubella, similar
immunogenicity problems were solved by developing
live attenuated vaccine strains [4-6]. For HIV and SIV,* Correspondence: ira.berkower@fda.hhs.gov
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reproduction in any medium, provided the orlive attenuated vaccines have been an attractive goal
[7,8], but they may incur risks due to proviral integration
and, in some cases, reversion to wild type virus [9,10].
Instead, live viral vectors with HIV vaccine inserts have
been proposed [11-14] to combine the growth and im-
munogenicity of the vector with the antigenicity of the
insert [15]. The live attenuated rubella vaccine strain
RA27/3 is a promising viral vector, as its safety and
immunogenicity have been established in clinical trials
[5,16]. One dose of rubella vaccine elicits strong
humoral and mucosal immunity and protects for life
against rubella infection. By presenting HIV and SIVtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Virnik et al. Retrovirology 2013, 10:99 Page 2 of 15
http://www.retrovirology.com/content/10/1/99vaccine inserts as rubella antigens, live rubella vectors
could enhance the immune response to these antigens.
We have recently identified two insertion sites in the
rubella genome, where a foreign gene could be inserted
without compromising rubella replication in cell culture
[17-19]. The vector constructs were based on the rubella
vaccine strain RA27/3 or on wild type rubella [20,21].
The first insertion site was located in the rubella non-
structural region, where a permissive deletion between
two Not I restriction sites [18,22] made room for an in-
sertion at the same site. The insert was expressed as a
fusion protein with nonstructural protein P150. This de-
letion/insertion strategy resulted in the first replicating
rubella vectors capable of expressing zGFP, the HIV
membrane proximal external region (MPER) determin-
ant, and SIV Gag antigens [17,18]. However, since each
insert was expressed as a fusion protein with P150, pres-
ervation of essential P150 functions could limit the size
and composition of the insert.
The second insertion site was located in the structural re-
gion, between envelope proteins E2 and E1 [19]. This site
uncoupled antigen expression from essential viral functions,
and it accommodated larger and more complex antigens.
At this site, insert expression was controlled by the strong
subgenomic promoter, resulting in high-level expression for
a longer duration. First generation vectors with a structural
site insert retained the Not I deletion. These vectors
grew to high titer in cell culture while expressing the insert
at a high level [19]. Yet, their replication in vivo was
compromised by the Not I deletion. New generation
vectors, with structural site inserts and the Not I deletion
restored, grew robustly in vivo, while expressing SIV and
HIV vaccine antigens at high levels.
The rubella vaccine strain RA27/3 readily infects rhe-
sus macaques [23]. The present study is the first to dem-
onstrate the growth and immunogenicity of rubella
vectors in macaques. The new generation rubella vectors
infected all animals tested. They elicited a strong im-
mune response to the SIV Gag insert, indicating the po-
tency of vaccine antigens expressed at the structural
insertion site. The antibodies were long lasting, and the
animals responded strongly to a vector boost, indicating
the induction of memory B cells. Rhesus macaques are
also susceptible to SIV or Simian-Human immunodefi-
ciency virus (SHIV) infection. This overlapping host
range will provide an ideal animal model for immunizing
with rubella vectors and testing protection against SIV
or SHIV challenge [24,25].
Results
Vector constructs: replication and expression in cell culture
The rubella genome is a 9.7 kb positive sense single-
stranded RNA (Figure 1A). Genes at the 5′ end code for
the nonstructural polyprotein, which is expressed undercontrol of the genomic promoter and cleaved by viral
protease (green arrow) to release mature nonstructural
proteins P150 and P90 [21]. The 3′ genes code for the
structural polyprotein, which is controlled by the strong
subgenomic promoter. The polyprotein is normally
cleaved at two sites by signal peptidase, to release ma-
ture structural proteins, capsid (33kDa), E2 (42–47 kDa)
and E1 (58 kDa).
Three types of vectors were produced, with MPER or
Gag sequences inserted into the RA27/3 rubella vaccine
background. Type 1 vectors had an insert at the struc-
tural site and a compensatory deletion at the Not I site,
as described previously [19]. Type 2 vectors had an
insertion and deletion at the Not I site in the non-
structural region of rubella [18]. The new type 3 vectors
have an insertion at the structural site, but they have no
deletion at the Not I site. Figure 1A shows the design of
a typical type 3 rubella vector. The insertion site is
located between envelope glycoproteins E2 and E1. The
inserted sequences code for MPER of HIV-1 [18,19,26,27]
or for an SIV Gag construct containing four T cell epitopes
linked together (called BC-sGag2) [18,19,28,29]. Each anti-
genic insert (labeled Ag in Figure 1A) is preceded by the
transmembrane domain of E2 (E2TM) and the signal
peptidase site of E1 (E1SP), and it is followed by another
transmembrane domain (TM) and E1SP peptidase site.
Signal peptidase cleavage at three sites in the structural
polyprotein (red arrows) would release the three rubella
structural proteins plus the vaccine insert.
Vector replication in Vero cells was monitored by
Western blot with antibodies to the rubella structural
proteins C and E1 (Figure 1B, left panel). Rubella vectors
expressing HIV MPER or SIV Gag antigen grew as well
as the vaccine strain without an insert (left panel). Ex-
pression of the MPER-HIVTM insert was detected with
anti-MPER monoclonal antibody 2F5 (Figure 1B, middle
panel). The MPER insert was strongly expressed as a 10
kDa band (yellow arrowhead), which was absent in the
empty rubella control (RA27/3, middle panel), and it
was comparable to gp41 in the AT-2 inactivated virus
control (SHIV, red arrowhead). Expression of the SIV
Gag insert was detected by cross-reaction with HIV im-
mune globulin (Figure 1B, right panel). The BC-sGag2
insert was expressed as a 14 kDa band (green arrow-
head), which was absent in the empty rubella control
(RA27/3, right panel) and was comparable to the control
band for recombinant p55 Gag (lane p55, blue arrow-
head). After 5 passages in cell culture, we expanded each
vector to create viral stocks expressing MPER or SIV
Gag inserts.
Rubella vector stocks for in vivo studies
We produced and characterized six rubella vector stocks
for monkey studies. We made two vectors of each type:
AB
Figure 1 Design of rubella vectors, their replication and expression of inserts at the structural site. (A) The non-structural genes are
located near the 5′-end of the genome (blue) and are controlled by the genomic promoter (Pgen). The structural genes are located near the 3′
end (yellow) and are expressed as a structural polyprotein controlled by the strong subgenomic promoter (Psub). The structural insertion site is
located between envelope glycoproteins E2 and E1. The antigenic insert (Ag, orange) is flanked on both ends by a transmembrane domain (red
or green) and signal peptidase cleavage sequence E1SP (blue). The structural polyprotein is cleaved at three sites by signal peptidase (red arrows)
to release mature structural proteins and the insert. (B) Replication of rubella vectors was demonstrated by Western blot of infected Vero cells
with antibodies to rubella proteins E1 and C (left panel). Expression of the MPER-HIVTM insert was detected with monoclonal 2F5 (middle panel),
while expression of the BC-sGag2-E2TM insert was detected with polyclonal HIV immune globulin (right panel). The control vaccine strain RA27/3
showed good growth (left panel), but no expression of either antigen (middle and right panels). The rubella-MPER vector replicated well (left
panel), while expressing MPER-HIVTM as a 10 kDa band (middle panel, yellow arrowhead). The rubella-BC-sGag2 vector also replicated well (left
panel) and expressed Gag as a 14 kDa band right panel, green arrowhead). Control lanes include AT-2 inactivated SHIV virions for gp41 (lane
SHIV, red arrowhead), recombinant p55 SIV Gag protein (lane p55, blue arrowhead), and uninfected cells (lanes N).
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The MPER insert at the structural site consisted of the
complete membrane proximal external region, followed by
the HIV transmembrane domain and an E1SP signal
sequence. At the nonstructural site, the MPER insert
consisted of the 2F5 epitope alone, without the 4E10 epi-
tope or transmembrane domain [18]. The SIV Gag insert at
the structural site consisted of four T cell epitopes linked in
tandem (called BCsGag2) followed by the E2TM domain of
rubella and the E1SP signal peptide [19], while the Gag in-
sert at the nonstructural site was BC-sGag2 alone. The se-
quences of all inserts are given in Figure 2. For each vector,
we demonstrated insert expression by Western blot.
The titers of type 3 vector stocks are shown in Table 1.
Viral RNA content was determined by quantitative RT-
PCR. The viral titers were estimated by comparing theirRNA concentration to that of a rubella reference sample of
known PFU titer. Viral titers were 7.7 × 106 PFU/ml, or
greater, which is equivalent to about 1500 human doses per
ml. This was 0.5 to 1 log greater than the viral titers
reported previously for type 1 vectors [18,19], and it sug-
gests that the new vectors replicate more robustly without
a Not I deletion. Viral sequencing showed that the insert
was stable and in reading frame after at least five passages.
In addition, Western blot showed stable expression of the
insert. The vector doses given to macaques, based on viral
titer, were between two and ten times the typical human
dose of rubella vaccine (about 5,000 PFU/dose).
Rubella vector replication in vivo
The protocol for testing rubella vector replication and
immunogenicity in vivo is shown in Figure 3. Macaques
Insert/vector name Amino acid sequence of the inserts







Structural insertion site (type 1 and type 3 vectors)b
MPER-HIVTM EEPRQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVF


















Figure 2 Antigenic inserts used in this study. Sequences of the core epitopes for broadly neutralizing antibodies 2F5 and 4E10 in HIV-1 MPER,
T cell epitopes in SIV Gag, membrane-spanning domains and signal peptides are underlined and labeled as in the text. a Described in [18]. b Type
1 vectors were described in [19].
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the control group of two animals. Group 1 received
three priming doses of DNA vaccine, followed by a boost
with rubella vectors. Group 2 received three doses of
DNA vaccine and were reserved for future study. Group
3 received a series of rubella vectors first, followed by
two doses of DNA vaccine. Group 4 controls received
the rubella vaccine strain twice (with no insert), followed
by empty DNA vaccine. Rubella vectors were given
pairwise: one vector expressed MPER and the other
expressed BC-sGag2, and both inserts were at the same
insertion site. The first vector was given at a dose ofTable 1 Titers of rubella vector type 3 stocks
Viral vector (passage) RNA copies/ml Estimated titer, PFU/ml
MPER-HIVTM (P5) 1.5 × 10
8 1.3 × 107
BC-sGag2-E2TM (P5) 8.5 × 10
7 7.7 × 10610,000 PFU initially, followed by 30,000 PFU for the sec-
ond dose. The second and third vectors were given at
50,000 PFU per dose (approximately 10 human doses).
At week 57, macaques in groups 1 and 4 were given a
boost with type 3 vectors to determine feasibility of
boosting.
The DNA vaccine consisted of SIV gag and HIV clade
B env at the first dose, clade C at the second dose, and
both clades for the third dose [30]. Mouth swabs were
taken before each dose of live rubella vectors and one
and two weeks after the dose to detect viral RNA by RT-
PCR. Blood samples were taken before each dose and
one, two and six weeks after immunization to analyze
the immune response to rubella proteins and to each
insert.
According to the protocol, group 3 macaques were the
first ones to receive live rubella vectors. We followed
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Figure 3 Rhesus macaque immunogenicity protocol. Macaques in group 1 received three doses of DNA vaccine, followed by a dose of
rubella vectors at week 25 and a boost at week 57. Group 2 received DNA vaccine alone and were reserved for future studies. Group 3 received a
series of three different rubella vectors, until the type 3 vectors gave a “take” in three out of three animals. They were boosted with two doses of
DNA vaccine, starting at week 25. Group 4 control animals received rubella vaccine strain RA27/3 as an “empty” vector control, followed by two
doses of control DNA plasmids, and a boost of rubella vectors at week 57.
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first two doses of type 1 vectors failed to elicit antibodies
to rubella (left panel). The next dose of type 2 rubella
vectors gave a partial “take” in one out of three animals
(CL6V). At this point, we replaced the seropositive ani-
mal with a naïve macaque (DCVV), in order to have
three rubella seronegative animals for the next injection.
The next dose consisted of type 3 vectors and was given
at week 18. All three animals promptly seroconverted,
indicating a vaccine “take”. Anti-rubella titers peakedVector type
1. structural site insert / Not I deletion
2. Not I site insert / Not I deletion
3. structural site insert / No deletion
Group 3
Figure 4 Immune response to rubella antigens as a measure of a vac
types of rubella vectors bearing inserts at different insertion sites (left pane
same live attenuated rubella vaccine strain but without an insert (right pan
anti-rubella antibodies, as measured by ELISA. Vector type 1, with a structu
after two vaccinations. Vector type 2, with insertion and deletion at the No
with a structural site insert and no deletion (green), infected all three macaafter 2 to 4 weeks (left panel, CL49, CL67, and DCVV).
The magnitude and kinetics of the anti-rubella response
elicited by live attenuated rubella vectors (left panel)
were similar to control macaques in group 4 that re-
ceived live attenuated rubella vaccine without an insert
(Figure 4, right panel). Type 3 rubella vectors retained
potency for rubella antigens while expressing vaccine
antigens at the structural site.
By week 25, group 1 macaques had been primed with
three doses of DNA vaccine, and they were ready for aGroup 4
cine “take”. Group 3 macaques were inoculated with a series of three
l). These were compared with group 4 macaques, which received the
el). A successful vaccine “take” was detected by the appearance of
ral site insert and Not I deletion (red), elicited no detectable antibodies
t I site (blue), gave a “take” in one of three animals. Vector type 3,
ques after a single dose.
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type 3 vectors that replicated in group 3. As before, all
three macaques promptly became infected with rubella
vectors. The vectors were injected in the quadriceps
muscle, and vector proliferation and dissemination were
tested a week later by RT-PCR of mouth swabs. Pre-
immunization swabs were all negative for rubella vectors
bearing the MPER insert (Figure 5 upper panel, lanes 1–
3). A control DNA plasmid containing the identical
MPER insert (lane 7) gave a PCR band at 347 bp. One
week after infection, two out of three macaques were
positive for this band (lanes 4 and 6), and the third
macaque became positive after two weeks (lane 9).
Similarly, there was no pre-immunization RT-PCR signal
for SIV Gag (lower panel, lanes 1–3). The plasmid con-
trol gave a band at 494 bp (lane 7). Two macaques be-
came positive for this band after one week (lower panel,
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Figure 5 Detection of systemic infection with rubella vectors
by RT-PCR. Group 1 macaques were immunized with live rubella
vectors given IM in the quadriceps, and gingival mouth swabs were
collected at 0, 1, and 2 weeks after immunization. Viral RNA
containing the MPER insert was amplified by RT-PCR, and the
products were resolved in 2% agarose gel. Lane 7 shows the PCR
band at 347 bp for a plasmid with the same MPER insert as in the
viral vector (upper panel). No virus was detected in pre-injection
samples (lanes 1–3, representing J6L, V200, and V584). One week
post infection, two of three animals were positive for virus (lanes 4
and 6). By week 2, both of these were resolved (lanes 8, 10), and the
third animal was positive (lane 9). Similar results are shown for RT-
PCR of the BC-sGag2 insert (lower panel), with a positive band at
494 bp for the plasmid control (lane 7). All animals were negative at
the start (lanes 1–3), two of three were positive at week 1 (lanes 5
and 6), and both had cleared by week 2 (lanes 9 and 10). We
detected no signal for BC-sGag2 from one of the macaques (J6L) at
either time point.signal for Gag at either time point (lanes 4 and 8). The
results showed three patterns: one macaque was positive
for both vectors at the same time and cleared the virus
by week 2 after vaccination (lanes 6 and 10 in both
panels); one macaque was positive for the SIV Gag vec-
tor first, and then for the MPER vector the following
week (lanes 5 and 9, both panels); and one macaque was
positive for the MPER vector, but never gave a signal for
SIV Gag (lanes 4 and 8, both panels). The results indi-
cate that two rubella vectors can grow side by side in the
same host. Since the vectors were given in the quadri-
ceps muscle and detected in mouth swabs one or two
weeks later, this result indicates systemic infection by ru-
bella vectors in all three animals. Failure to detect a PCR
signal for the rubella-Gag vector in one macaque is not
surprising for this method, which depends on the sensi-
tive detection of low virus titers in the mouth [16,31].
Immunogenicity of Gag vector inserts
The antibody response to the SIV Gag insert was mea-
sured by ELISA assay on plates coated with recombinant
SIV p55 Gag protein (Figure 6). High-titered antibodies
to SIV Gag were elicited in all six macaques in group 3
(Figure 6A) and group 1 (Figure 6B). The antibodies
were not observed in pre-bleeds or in control animals
that were immunized with rubella vaccine lacking an in-
sert (macaque CL6A), indicating that the antibodies
were made in response to the insert. The anti-Gag titers
from three vector-immune macaques in group 1 were
greater than or equal to a pool of positive sera from six
SIVmac251 infected macaques (Figure 6B). Unlike SIV
infection, which exposes macaques to the full-length
Gag protein, the BC-sGag2 vector covered only 20% of
the Gag sequence, yet it elicited antibody titers compar-
able to infection.
We compared three vaccinated macaques (two from
group 3 and one from group 1) with a panel of five ma-
caques infected with SIVmac251 (Figure 6C). In each
case, immunization with Gag vectors elicited anti-Gag
antibodies with higher maximum ODs by ELISA and
similar endpoint titers as those induced by natural SIV
infection. This result indicates the potency of vaccine
antigens expressed at the structural insertion site of live
rubella vectors.
The kinetics of the response to SIV Gag are shown for
individual macaques (Figure 7) to illustrate the differ-
ence between live and non-replicating rubella vectors.
Two animals, DCVV (group 3) and V584 (group 1),
demonstrate the sustained response elicited by a single
dose of live rubella vectors (Figure 7A and B). For
DCVV, anti-Gag antibodies rose between 2 and 4
weeks and reached a peak 7 weeks post immunization
(Figure 7A). For macaque V584, which received three
priming doses of DNA vaccine, a good anti-Gag titer
A B C
Figure 6 The immune response to the SIV Gag insert was measured by ELISA on plates coated with recombinant p55 SIV Gag protein.
(A) Group 3 macaques, which received rubella vectors alone (live vector + 7 weeks), or (B) group 1 macaques, which received DNA prime and
rubella vector boost (live vector + 4 weeks), produced high-titer anti-Gag antibodies in six out of six animals, as compared to the positive control
from a pool of SIV infected macaques. The rubella vaccine control (CL6A empty in panel A) elicited no antibodies. (C) Anti-Gag antibody titers in
three immunized macaques from groups 1 and 3 (four weeks after live vector, solid lines) were compared to a panel of four macaques infected
32 weeks earlier with SIV and a pool of infected macaques (dotted lines). Anti-Gag titers elicited by vector immunization were comparable to the
antibodies elicited by SIV infection.
A B
C D
Figure 7 Antibody response to replicating (A and B) and non-replicating (C and D) rubella vectors. (A) Macaque DCVV received a single
dose of replicating vectors. Anti-Gag antibodies were detectable 2 weeks post immunization and they rose progressively by weeks 4 to 7. (B)
Macaque V584 was primed three times with DNA vaccine, which elicited a good antibody response, and these titers rose substantially between 2
and 4 weeks after a single dose of live vectors. (C, D) Macaques CL6V and CL67 received three doses of non-replicating vectors. Antibodies were
barely detectable after the first dose (5 weeks post immunization), but titers rose progressively after the second (4 weeks post immunization) and
third doses (2 weeks post immunization), eventually reaching the same levels as a single dose of live vectors.
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an even stronger anti-Gag response to the live vector
that increased steadily between 2 and 4 weeks post
immunization (Figure 7B). The specificity of these
antibodies for SIV Gag was demonstrated by Western
blot (19).
In contrast, macaques CL6V (Figure 7C) and CL67
(Figure 7D) were initially given two doses of non-
replicating type 1 vectors that expressed the same inserts
at the same site as the replicating vectors, followed by a
third dose with a type 2 vector. Both macaques made a
minimal response to the first dose of non-replicating
vectors. However, two or three doses of non-replicating
vectors could achieve the same antibody titers as a single
dose of the same insert in a live vector.
Immunogenicity of MPER vector inserts
The antibody response to the HIV MPER insert was
measured by ELISA on plates coated with gp140 SOSIP
trimers (Figure 8). High-titered antibodies to MPER
were elicited in five out of six macaques in group 3
(Figure 8A) and group 1 (Figure 8B), while one animal
showed a moderate response. The antibodies were not
observed in pre-bleeds or in control animals that re-
ceived rubella vaccine without an insert (CL6A control).
The antibodies were specific for the external domain of
gp41, since they bound gp140 but not gp120. The anti-
bodies may be specific for MPER determinants in gp140
trimers: they bound SOSIP gp140, which are enriched in
trimers [32], but they did not bind monomeric peptides
containing the 2F5 and 4E10 epitopes (Figure 8B).
Antibody persistence
We measured the persistence of anti-Gag antibodies in
group 3 macaques for nine months after immunization.Figure 8 The immune response to the MPER HIV-1 insert. Five out of s
antibodies in response to the MPER insert. One animal showed a moderate
immunization with replicating vectors in group 3 macaques and four week
control (CL6A) elicited no antibodies, indicating specificity for the insert. No
specificity for the MPER insert. However, the group 1 antibodies did not bin
epitopes, and similar results were obtained with group 3 antibodies.We compared this to the persistence of anti-rubella anti-
bodies in the same animals (Figure 9). Anti-rubella titers
in all three macaques (Figure 9A, C and E) peaked 4 to
7 weeks after immunization. Based on midpoint titers,
the antibodies declined about 3-fold by 15 weeks post
immunization for DCVV and CL67 and then remained
constant until 38 weeks. The decline was greater for
CL49, about 9-fold by 15 weeks and another 3-fold by
38 weeks.
We measured anti-Gag antibodies in the same ma-
caques at the same time points (Figure 9B, D, and
F). Anti-Gag antibodies peaked 4 to 7 weeks post
immunization (week 22 to 25 of the study) and then de-
clined 3-fold or less by 15 weeks. By 38 weeks post
immunization (study week 56), they declined another 3-
fold or less in two macaques (DCVV and CL49) and 5-
fold in the other (CL67). In two macaques (DCVV and
CL49), the durability of anti-Gag titers was greater than
or equal to anti-rubella titers, and in one case (CL67)
anti-Gag titers were less durable over a 9 month period.
This suggests that the persistence of anti-Gag antibodies
could be comparable to anti-rubella antibodies, which
are known to be long-lasting [16]. The durability of anti-
Gag antibodies between 7 and 15 weeks after vaccin-
ation may be due, in part, to two boosts of DNA vaccine
given during this time. However, this would not account
for the continued stability observed during weeks 15 to
38 post vaccination, when DNA vaccine was not given.
We measured the persistence of anti-MPER antibodies
in the same group 3 macaques at the same time points
(Figure 10A, B, and C). Anti-MPER antibodies reached
high titers by 4 to 7 weeks post immunization. The titers
changed very little at 15 weeks, when all three animals
were within two-fold of the peak titer. By 9 months,
the antibodies declined 2 to 3-fold, as judged by half-ix macaques in group 3 (A) and in group 1 (B) produced high-titered
response. The sera were tested four to seven weeks after
s after live rubella vectors in group 1. The empty rubella vaccine
binding to gp120 was observed in any serum, indicating antibody
d monomeric MPER peptides corresponding to the 2F5 and 4E10
A C E
B D F
Figure 9 Persistence of anti-rubella and anti-Gag antibodies elicited by rubella vectors in group 3 macaques. The midpoint titers of anti-
rubella antibodies (A, C, E) and anti-Gag antibodies (B, D, F) were measured for each animal between weeks 22 to 56 of the study,
corresponding to weeks 4 to 38 after rubella immunization. Both antibodies peaked by 4 to 7 weeks after immunization. For DCVV, the decline in
rubella antibodies and anti-Gag antibodies were both less than 3-fold over 34 weeks. For CL49, anti-Gag antibodies declined about 3-fold, while
the decline in rubella antibodies was much greater. For CL67, anti-Gag antibodies declined about 13 -fold, which was greater than the decline in
anti-rubella titers.
A B C
Figure 10 Persistence of anti-MPER antibodies elicited by rubella vectors in group 3 macaques. Anti-MPER antibody titers were measured
for group 3 animals, DCVV (A), CL49 (B) and CL67 (C), between weeks 4 and 38 after live vector immunization. The same sera were tested as in
Figure 9. The antibodies were near peak titers at 4 to 7 weeks post immunization. The titers declined 2 to 3-fold by 38 weeks, based on half-
maximum binding, and this was nearly the same as anti-rubella antibodies in the same animals.
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was comparable to anti-rubella antibodies, at least for
the first nine months post immunization.
Response to a rubella vector boost
We waited up to a year for rubella antibodies to decline
to a level where we could boost with rubella vectors
bearing new antigens. For group 4 macaques, these anti-
bodies declined about 2.5-fold after 6 months, and then
remained constant or rose slightly by 1 year. After one
year (group 4) or 6 months (group 1), we boosted the
macaques with rubella vectors expressing MPER and
SIV Gag antigens (week 57 of the study). All five animals
showed a prompt rise in antibodies to rubella (data not
shown).
We measured the anti-SIV Gag antibody response four
weeks after the boost (week 61 of the study, Figure 11).
For group 4 animals primed with empty rubella vaccine,
the BC-sGag2 boost represented new antigens that were
not seen previously. Neither macaque made anti-Gag
antibodies (Figure 11A), suggesting that the vector could
not elicit a primary response in the presence of rubella
antibodies. The group 1 animals were quite different:
they all had antibody titers to SIV Gag that were primed
six months earlier (Figure 11B). In addition, they
responded strongly to the live vector boost, despite the
presence of rubella antibodies. In this group, the boost
consisted of novel type 3 vectors expressing Gag as a
combined MPER–BC-sGag2 antigen (Figure 2) or as the
complete Gag protein p27. The results suggest that the
gag DNA prime and first dose of live rubella vectors
elicited memory B cells specific for SIV Gag antigens.
These memory B cells were strongly boosted upon re-A
Figure 11 Anti-Gag response to a live vector boost. (A) Group 4 macaq
They were boosted at week 57 with rubella vectors expressing BC-sGag2-E
with DNA vaccine, followed by a live BC-sGag2 vector at week 25. They we
sGag2-E2TM fusion protein and the entire p27 Gag protein. Animals primed
respond to the BC-sGag2 boost. Animals primed with gag DNA and rubella
symbols), and they responded strongly to the boost (solid symbols). This in
recalled by the boost.exposure to the vectors, even in the presence of rubella
antibodies. The inability of control macaques (group 4)
to respond in this way showed a lack of memory B cells.
Discussion
Live attenuated rubella vaccine has a proven record of
safety and immunogenicity in humans and rhesus ma-
caques. This small RNA virus would be an attractive
viral vector, if it could present the major vaccine anti-
gens of other viruses as well as its own. This is the first
report showing that live attenuated rubella vectors repli-
cate robustly in vivo while expressing SIV and HIV vac-
cine antigens. The new vectors infected six out of six
rhesus macaques, while eliciting high-titered antibodies
to the SIV Gag insert in all of them and to HIV MPER
in five out of six. The anti-Gag antibody titers elicited by
immunization were greater than or equal to those in-
duced by natural infection with SIV. The antibodies to
both inserts have persisted for over 9 months, and they
have declined at the same rate as antibodies to rubella,
which protect for life. The anti-Gag antibody response
was boosted by re-exposure to the vector after six
months, indicating the induction of memory B cells.
Since rhesus macaques are also susceptible to SIV infec-
tion, they will provide an ideal model for testing im-
munogenicity of novel rubella vectors and protection
against SIV or SHIV challenge.
At the start of these studies, rubella vectors faced a
series of questions before they could be considered a
vaccine candidate. These included: location of insertion
sites, size and stability of inserts, adaptation to the live
attenuated vaccine strain, replication in vivo, immuno-
genicity, and concurrent immunization with more thanB
ues were primed with the rubella vaccine strain at 0 and 5 weeks.
2TM and HIV MPER. (B) Group 1 macaques were primed three times
re boosted at week 57 with novel vectors expressing an MPER–BC-
with empty rubella vaccine had no antibodies to Gag and failed to
expressing BC-sGag2 had persistent antibodies at week 57 (open
dicates that DNA/rubella priming induced memory B cells, which were
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could grow to high titers in cell culture while expressing
SIV and HIV antigens at either of two insertion sites
[18,19]. Inserts at the Not I site in the nonstructural re-
gion included zGFP, SIV Gag epitopes, and HIV MPER
[17,18]. These inserts were limited in size and diversity,
probably because they were expressed as fusion proteins
with rubella nonstructural protein P150, which performs
essential viral functions.
However, when the genes were inserted in the struc-
tural region, between envelope glycoproteins E2 and E1,
insert expression was uncoupled from essential viral
functions. This allowed the expression of larger inserts
[19]. These inserts were expressed as part of the
structural polyprotein under control of the strong
subgenomic promoter, leading to high-level antigen ex-
pression for a prolonged period. When we switched to
the rubella vaccine strain RA27/3, the new vectors were
able to express the same inserts as wild type rubella,
with little or no loss in vector titer, antigen expression,
or insert stability [18]. The vectors with Not I deletion
did not replicate well in vivo. This was solved by restor-
ing the deleted sequence, which resulted in replication
of type 3 vectors in six out of six macaques. The deleted
sequence is part of the “Q” domain in nonstructural pro-
tein P150 with unknown function [33]. This region may
be important for interferon signaling or suppression.
Vectors with the Not I deletion replicate well in Vero
cells, which are incapable of interferon production, but
they do not replicate in normal WI38 or BSC-1 cells
(Virnik et al., manuscript in preparation). Future studies
will address this phenomenon.
Live replicating rubella vectors expressing SIV Gag or
HIV MPER at the structural insertion site were highly
immunogenic in macaques. These vectors could contrib-
ute to vaccine potency at each stage of the immune
response: by simulating acute infection and triggering
innate immunity, they could initiate a stronger immune
response to the inserts. Subsequently, exponential growth
of the vector would expose the host to increasing doses of
antigen each day. Finally, prolonged antigen expression can
mimic an ongoing infection [14,15], leading to germinal
center formation, which is needed for immunoglobulin
class switching, somatic hypermutation to produce high-
affinity antibodies, and maturation of memory B cells [34].
Unlike their non-replicating homologues, live rubella vec-
tors elicited anti-Gag antibodies after a single dose, and the
antibody titers continued to rise for four to seven weeks
after immunization. These strong stimuli, lasting two weeks
or more, explain how live vectors could achieve the same
high titers of anti-Gag antibodies as natural SIV infection.
With some other vaccines and vectors, the immune
response to SIV and HIV antigens has been short-lived
and lacked memory B cells [35,36]. Transient antibodyresponses are considered one of the major obstacles to
HIV vaccine development [1]. Using live rubella vectors,
the anti-Gag and anti-MPER antibodies have persisted
for over nine months. They are declining with nearly the
same half-life as antibodies to rubella proteins, which
protect for life. In general, persistent antibody titers are
thought to depend on long-lived plasma cells, while
boosting depends on memory B cells, and both are signs
of germinal center function during immunization [34].
The primary immune response to these vectors included
memory B cells, as shown by boosting 6 months later.
The secondary response depended on successful prim-
ing, and it could overcome the inhibitory effects of ru-
bella antibodies. Potentially, two or more doses of live
rubella vectors, given several years apart, could boost
and update immunity to circulating strains of HIV. In
addition, the ability to prime and boost memory B cells
would allow us to combine rubella vectors with other
viral vectors bearing similar HIV vaccine inserts [37,38],
and this will be tested.
Rubella is a small RNA virus that replicates exclusively
in the cytoplasm. This location is ideal for eliciting T cell
immunity, since it delivers antigens directly into the
proteasomal pathway leading to antigen presentation
with MHC class I [39]. Priming with DNA vaccine and
boosting with the vector gave high levels of Gag specific
CD8+ T cells that were comparable to natural infection
(Virnik, et al., manuscript in preparation). When two
rubella vectors were given simultaneously, they both
replicated side by side, as shown by RT-PCR, and they
elicited antibodies to both Gag and MPER inserts.
Prolonged expression of MPER antigen by rubella vec-
tors may contribute to its immunogenicity and may im-
prove on natural infection, which elicits these antibodies
in less than half of the cases [40-43].
The safety and immunogenicity of live attenuated ru-
bella vaccine were demonstrated in rhesus macaques
[23] and in children [5,6,16]. Macaques have shown no
signs of disease during successful immunization with ru-
bella vectors. The safety of rubella vectors should be
comparable to rubella vaccine: if a rubella vector lost its
insert, it would revert to the vaccine strain. Given the
overlapping host range, rhesus macaques will provide an
ideal animal model for testing rubella vectors for im-
munogenicity and protection against SIV or SHIV chal-
lenge. Novel vectors that demonstrate vaccine potency
in macaques could be quickly translated into human
vaccine design.
Conclusions
We have completed the first successful trial of live ru-
bella vectors in rhesus macaques. Rubella vectors repli-
cated well in all macaques tested and they provide a
potent vaccine platform for immunizing with SIV and
Virnik et al. Retrovirology 2013, 10:99 Page 12 of 15
http://www.retrovirology.com/content/10/1/99HIV antigens. These vectors have a number of desirable
properties for a vaccine candidate, including: the ability
to immunize with more than one antigen at a time. The
vectors have shown vaccine potency comparable to nat-
ural SIV infection. They elicited long lasting immunity
and induced memory B cells that can be boosted months
later. They are built on a vaccine platform with known
safety and immunogenicity. Due to the overlapping host
range of rubella and SIV, rhesus macaques will provide
an ideal animal model for testing novel rubella vectors
for immunogenicity and protection against SIV or SHIV
challenge.Methods
Antigens antibodies and cells
Aldrithiol-2 inactivated SHIV virions with 89.6 envelope
and SIV Gag proteins were a kind gift of Drs. Larry
Arthur and Jeffrey Lifson at the AIDS Vaccine Program,
NCI [44]. Recombinant p55 SIV Gag protein, anti-
MPER monoclonal antibody 2F5 [26] and anti-HIV
polyclonal antibodies used for BC-sGag2-E2TM detec-
tion were provided by the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID.
Well-characterized recombinant gp140 SOSIP trimers
[32] were a kind gift of Dr John Moore, Weill Medical
College of Cornell University (New York, NY). Monoclonal
2F5 was also provided by Dr. Hermann Katinger, Polymun
Scientific (Klosterneuburg, Austria). Polyclonal goat anti-
bodies to rubella structural proteins were purchased from
Fitzgerald Industries International, Inc. (Concord, MA).
Vero cells were obtained from the American Type Culture
Collection (Manassas, VA).Construction of vectors with inserts in the structural site
The derivation of type 1 and type 2 rubella vectors were
described previously [18,19]. Type 3 vectors were de-
rived from type 1 vectors by cutting out the Not I de-
leted Hind III-Bgl II fragment from the plasmid DNA
encoding type 1 vectors and replacing it with the corre-
sponding intact fragment from the p10RA plasmid cod-
ing for the RA27/3 vaccine strain of rubella [20]. For
these vectors, the MPER insert was followed by the
transmembrane domain of HIV-1 gp41 (MPER-HIVTM
vector) and the E1 signal peptide. The BC-sGag2 insert
consisted of four T-cell epitopes in tandem (GY9, TE15,
CM9 and ME11 of SIV mac239 Gag), followed by the
transmembrane domain of E2 (BC-sGag2-E2TM vector),
and the E1 signal peptide (Figure 1A). All constructs
were verified by sequencing, as described previously
[19]. The insert sequences are provided in Figure 2. In
addition to previously described inserts, one new insert
combined the MPER determinant and the BC-sGag2 de-
terminant in tandem. Another insert consisted of full-length p27 SIV Gag, containing amino acids 135–391 of
SIVmac239 Gag, followed by to the E2TM domain.
The protocols for generating infectious rubella RNA
from plasmid DNA, transfecting cells, passaging virus in
Vero cells, viral stock expansion, sequencing the inserts,
determining viral RNA content of rubella vector stocks
and their titers were the same as described previously
[17,18]. Briefly, we transcribed plasmid DNA in vitro to
produce capped infectious rubella RNA, using RiboMAX
Large scale RNA Production System with Ribo m7G(5’)
ppp(5’)G cap analog (Promega Corp., Madison, WI). To
generate rubella virus, the RNA was transfected into Vero
cells, using DMRIEC reagent (Invitrogen Corporation,
Carlsbad, CA). After 6–9 days of infection at 37°C, culture
supernatant containing virus (passage P0) was collected.
Infected cells were transferred onto fresh Vero cells to start
a new passage. After several passages, passaging was done
with cell-free culture supernatant. To produce virus stock,
virus production was scaled up in T75 flasks after 5–6
passages. The supernatant was collected, titered by quanti-
tative RT-PCR and the vector insert was sequenced. Purifi-
cation of viral RNA from viral supernatants and reverse
transcription were performed using QIAamp UltraSens
Virus kit (QIAGEN) and High Capacity RNA-to-cDNA
Kit (Applied Biosystems), respectively. The cDNA was
PCR amplified with illustra PuReTaq Ready-To-Go
PCR beads (GE Healthcare) and primers specific for
rubella sequences flanking an insertion site, then
purified in agarose gel and sequenced using the same
primers.
Detection of rubella growth in cell culture and insert
expression by Western blot
Rubella structural proteins were detected by Western
blot with goat anti-rubella antibodies specific for capsid
protein C and envelope protein E1, as described previously
[17,18]. Expression of the MPER-HIVTM and BC-sGag2-
E2TM inserts was detected with human monoclonal anti-
body 2F5 at 1 μg/ml and anti-HIV polyclonal antibodies at
1:2500 dilution, respectively. The second antibody was ei-
ther horseradish peroxidase-conjugated rabbit anti-goat
IgG or goat anti-human IgG at 1:5000 dilution (Santa Cruz
Biotechnology, CA). Blots were visualized with enhanced
chemiluminescence (GE Healthcare).
Animals and immunizations
Rhesus macaques, between 3 and 16 years of age were
obtained from the CBER NHP colony on the NIH cam-
pus. All but two were of Indian origin; the two of un-
known origin were V200 and V584. The CBER animal
research program is fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC). All experimental proce-
dures were approved by the CBER Institutional Animal
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with the current edition of the Guide for the Care and Use
of Laboratory Animals. To be selected for the study, all ani-
mals passed a screening complete physical exam and a
veterinary evaluation of their medical history including
serology. Animals were negative for antibodies to rubella,
herpes B, STLV-1, SIV, SRV (type D, serology/PCR) 1, 2
and 3. During the study period, the animals were negative
for Shigella, Salmonella, Yersinia, Campylobacter and tu-
berculosis (TB) and free of intestinal pathogenic parasites.
Depending on their size, the macaques were housed in
6–12 sq ft cages and were habituated for more than 3
months. Before entry into the study, all macaques were
weighed and tissue typed. They were confirmed sero-
negative for SIV Gag and rubella antibodies prior to
receiving the vectors. All animals received ketamine
anesthesia (10 mg/kg/im) for restraint during immunization,
bleeding and taking oral swabs.
The 12 macaques were divided into three vaccine
groups of three to four each and a control group of two
animals (Figure 3). Group 3 was immunized first, with a
series of three different rubella vectors, until they
showed signs of a vaccine “take”, followed by two doses
of DNA vaccine. Group 1 received three doses of DNA
vaccine first, followed by one dose of type 3 vectors, the
same ones that gave a “take” in group 3. Group 2 re-
ceived three doses of DNA vaccine and was reserved for
future studies. Immunizations were at weeks 0, 5, 11, 18,
25, and 31. Two animals in group 4 received the licensed
rubella vaccine, which served as a vector control without
an insert, followed by control DNA.
For group 1 macaques, the first two doses of DNA vac-
cine consisted of four plasmid DNAs: 1 mg DNA coding
for SIV gag, 1 mg env DNA (gp140 and gp160), and 200 μg
coding for monkey IL-12 [45]. The first dose had env DNA
of clade B, while the second dose had clade C env DNA,
and the third dose had equal parts of env DNA of both the
B and C clades. For the animals in group 3, both DNA
boosts contained env DNA of the B and C clades. All
DNAs were given by intramuscular injection followed by
in vivo electroporation using the Elgen 1000 device (Inovio
Pharmaceuticals, Inc., Blue Bell, PA).
Each rubella dose consisted of a pair of rubella vectors of
the same type, expressing HIV MPER and SIV Gag deter-
minants. For group 3, the first rubella dose consisted of
type 1 vectors, given IM at a dose of 10,000 PFU, followed
by a second dose of 30,000 PFU. The next dose was a type
2 vector at 50,000 PFU. Finally, the type 3 vectors were
given IM at a dose of 50,000 PFU. Group 1 animals re-
ceived three doses of DNA vaccine, followed by a single
dose of type 3 vectors at 50,000 PFU. This corresponds to
about ten times the typical human dose of rubella vaccine.
Blood samples were taken before each vaccine dose and
one, two and six weeks after the dose. Mouth swabs werealso taken before each dose of rubella vector and one and
two weeks later. The blood samples were analyzed by
ELISA for antibodies to rubella, SIV Gag and HIV MPER.
They were also analyzed by tetramer staining for T cells
specific for the CM9 epitope. Mouth swabs were analyzed
by RT-PCR using primers specific for the gag and MPER
inserts.Detection of rubella virus in oral fluid specimens from
rhesus macaques
To determine whether rubella virus inoculated in the quad-
riceps muscle could propagate throughout the body, we
used a reverse transcription semi-nested PCR method to
detect rubella sequences in oral fluid specimens from im-
munized rhesus macaques. The oral fluid specimens were
obtained as gingival mouth swabs, using cotton swabs prior
to each dose of vectors, and again one and two weeks later,
using the procedure recommended by CDC [46,47]. After
the collection, the sample swabs were immersed in TRIzol
LS reagent (Ambion/Life Technologies, Carlsbad, CA) to
preserve viral RNA, stored frozen at −80°C or promptly
processed. RNA isolation was done according to the manu-
facturer’s protocol except for RNA precipitation step. Final
steps of RNA isolation were done using RNeasy Mini
Kit (QIAGEN, Valencia, CA) following the manufacturer’s
RNA cleanup protocol. The final volume of elution
was 60 μl. Reverse transcription was performed using
ThermoScript RT-PCR System (Invitrogen/Life Tech-
nologies, Grand Island, NY) with 9 μl of the isolated
viral RNA and gene-specific primers Robo-seq25, Robo-
seqSbfDn4. The nested PCR was a two-step PCR using
cDNA from the previous RT step and two outer primers
Robo-seq25 and Robo-seqSbfDn2 complimentary to the
flanking regions of the antigen inserts in the first step PCR.
The cDNA was amplified for 10 cycles (20 s at 95°C, 20 s at
65°C and 40 s at 72°C) and then for 20 cycles at a different
temperature profile (20 s at 95°C, 20 s at 61°C and 40 s at
72°C). The second step PCR was done with one primer spe-
cific to the insert (MPERF-seq1 for MPER-HIVTM and
Robo-K241 for BC-SGAG2-E2TM) and Robo-seqSbfDn2
primer from the first step, using 1/50 of the first PCR prod-
uct for 35 cycles (20 s at 95°C, 20 s at 60°C and 40 s at
72°C). PCR amplification was performed using a puReTaq
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The products from the second PCR reaction were resolved
by electrophoresis in 2% agarose gel. Sizes of the specific
PCR products after the second PCR step were expected to
be 347 bp for MPER-HIVTM insert and 494 bp for BC-
SGAG2-E2TM insert. A positive control consisted of a
plasmid coding for each insert and flanking parts of rubella.
Primer sequences are given in Table 2.
Serum enzyme-linked immunosorbent assay
Monkey antibodies to rubella were detected by ELISA in
duplicate wells, as measured on plates coated with ru-
bella antigens (BioCheck, Inc., Foster City, CA) at the
recommended serum dilution of 1:40. Macaque anti-
bodies to SIV Gag were detected on plates coated with
recombinant p55 Gag protein. For this assay, soft plastic
plates were coated with 1 μg/ml recombinant p55 SIV
Gag overnight at 4°. They were blocked for 5 minutes
with BSA (10 mg/ml). The antibodies were then titered
on the plates in PBS with 0.1 mg/ml BSA and 0.05% Tri-
ton X100. Macaque antibodies to HIV MPER were
detected on plates coated overnight at 4° with recombin-
ant gp140 SOSIP trimers at 1 ug/ml.
Macaque antibodies to MPER peptides were titered on
plates coated overnight with two peptides of 14 to 16
amino acids containing the 2F5 and 4E10 epitopes. For
each antigen, the plates were incubated with antibodies
for 1 hour at 37°, washed twice with the above buffer,
and developed with goat anti-monkey IgG conjugated to
horseradish peroxidase at a 1:5000 dilution (Santa Cruz
Biotechnology, CA). After 30 minutes at 37°, the plates
were washed four times and developed with TMB sub-
strate (SureBlue, KPL, Gaithersburg, MD). After ten mi-
nutes at room temperature, the reaction was stopped
with 1M HCl, and OD450 was determined in an ELISA
plate reader (Thermo Scientific).
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